
Mallinckrodt Pharmaceuticals has hit the headlines for particularly dispiriting reasons – with further evidence of practise by some companies that …

Imprimis Pharmaceuticals has announced that it has made available a customisable compounded formulation of pyrimethamine and leucovorin accessible for physicians …
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
Danish medical cannabis use rises as regulator reports no new safety signals

